tbuckley/cabot-search huggingface dataset:
Minimal residual disease assessment in colorectal cancer (MiRDA-C).
Authors: Arvind Dasari, Maen Abdelrahim, Jared David Acoba, Krishna Chaitanya Alluri, Tomislav Dragovich, Syed Mohammad Ali Kazmi, Benjamin Leon Musher, Ryan Sun, Lucas Wong, Y. Nancy You, Robert Anthony Zaiden, Scott Kopetz
Journal: Journal of Clinical Oncology (2022)

TPS236 Background: Detection of circulating tumor DNA (ctDNA) in the bloodstream is emerging as a novel marker for identifying of radiographically occult microscopic or minimal residual disease (MRD) in colorectal cancer (CRC) patients (pts) after curative intent treatments. Accumulating data suggest that ct-DNA defined MRD is a highly specific prognostic biomarker for future recurrences with a lead time of several months and prospective clinical trials are being conducted using ct-DNA defined MRD as an integral biomarker for improving risk stratification for adjuvant chemotherapy decision making. However, large scale, prospective data regarding kinetics of ctDNA-defined MRD with accurate pre-analytical methodology for plasma isolation and paired clinical data are limited. Methods: In this multi-center, prospective observational study, 1,000 pts with resectable CRC (stages II – IV) without other active malignancies undergoing therapy with curative intent will be enrolled any time from time of diagnosis up to start of adjuvant therapy (or ≤ 3 months post curative surgery, whichever is earlier). All therapeutic and surveillance visits decisions are at the discretion of the treating physicians. Serial biospecimens including blood (in Cell-Free DNA BCT tubes) to be processed to plasma and buffy coat in ≤ 2 days and formalin fixed tumor tissue will be collected at key time points until the time of radiographic recurrence or up to 5 years of surveillance. Blood draws will be at study entry, after each line of neoadjuvant therapy, post-surgery, during and after adjuvant therapy in addition to each surveillance visit. These blood draws will be coordinated with pts’ standard of care visits in order to minimize additional venipunctures. Relevant clinical data including demographics, cancer history, treatment details and outcomes, serum tumor markers and genomic data will be collected at each time point. Samples will be evaluated retrospectively with a primary objective of evaluating sensitivity and specificity of post-operative MRD for radiographic recurrences utilizing Guardant Health’s Reveal assay. Other key objectives include evaluating ctDNA kinetics with neoadjuvant and adjuvant therapies and to correlate with outcomes. The study is active, and enrollment is ongoing. Clinical trial information: NCT04739072.
Advanced imaging to assess longitudinal vascular changes in brain metastases treated with checkpoint inhibition.
Authors: Albert Eusik Kim, Ken Chang, Kyrre E. Emblem, Jayashree Kalpathy-Cramer, Eudocia Quant Lee, Nancy U. Lin, Sara M. Tolaney, Lakshmi Nayak, Ugonma Nnenna Chukwueke, Kevin S. Oh, Helen Alice Shih, Michael White, Don P. Lawrence, Beverly Moy, Justine Vanessa Cohen, Anita Giobbie-Hurder, Daniel P. Cahill, Ryan J. Sullivan, Priscilla Kaliopi Brastianos, Elizabeth Robins Gerstner
Journal: Journal of Clinical Oncology (2021)

3059 Background: Immune checkpoint inhibitors (ICI) have recently been shown to be effective for brain metastases (BM) in melanoma and lung cancer. Several studies demonstrate that 20-50% of BM patients respond to ICI. The reasons behind this wide variability in treatment response is not clear. Therefore, using physiologic imaging, we seek to identify the longitudinal biological changes exerted on BM as a result of ICI administration. Methods: Given the importance of aberrant tumor vasculature in cancer proliferation, we have focused on assessing changes in vascular physiology. We analyzed standard post-contrast and dynamic susceptibility contrast (DSC) MRI to identify characteristic vascular signatures as part of an ongoing Phase 2 study of pembrolizumab for patients with untreated or progressive, previously treated BM from any histology. Tumor volume measurements were calculated by summating all enhancing voxels. As per modified RECIST and RANO criteria for immunotherapy, volumetric increase of &gt; 40% was defined as progressive disease (PD), a decrease of &gt; 60% as partial response (PR), and stable disease (SD) as between -60% and +40%. Results: 35 patients, out of the total cohort of 60, have undergone DSC-MRI analysis. Histologies include 15 with breast cancer, 6 with non-small cell lung cancer, 4 with melanoma, and 10 with other cancers. At baseline, the total number of BM was 1-50+ per patient. Based on summing the entire enhancing intracranial disease burden, best volumetric responses for the 35 evaluable patients include 4 PR, 12 SD, and 19 PD. Thus far, we found that ICI-resistant BM had a 50% increase in cerebral blood flow (CBF), 105% increase in cerebral blood volume (CBV), a 15% increase in mean transit time (MTT), and an 80% increase in vessel caliber at 6 weeks post-treatment. On the other hand, ICI-responsive BM had no change in CBF, a 33% increase in CBV, a 10% decrease in MTT, and no change in vessel caliber. Ongoing analysis to uncover additional vascular changes (e.g. tumor oxygenation, vessel size index) within BM to ICI are pending. Conclusions: Our data provides evidence that effective ICI for BM is associated with unique intra-tumoral vascular physiology. With final analysis, we will uncover other facets of vascular physiology that correlate with ICI response, and may reveal mechanisms of response/resistance within tumors to ICI.
Combining CW doppler with a digital semiautomatic method for analysis of digital color M-mode images provides a dynamic measurement of effective orifice area: An in vitro validation study with a physiologic mitral regurgitation phantom Xiang-Ning Li, Xiaokui Li, Paul R. Detmer, David J. Sahn. Oregon Health Sciences University, Portland, OR
Journal: Journal of the American College of Cardiology (2001)
Sipple syndrome and pregnancy
Authors: R. E. Harris
Journal: JAMA (1976)

Sipple syndrome is an unusual entity during pregnancy. To our knowledge, this is the second case report of a pregnant patient with signs of Sipple syndrome. During pregnancy, this syndrome may present unusual complications, which require informed physician expertise for appropriate management. Our patient had a strong family history for Sipple syndrome, which is considered to be transmitted as an autosomal dominant. Thus, other family members, including the patient's offspring, must be assessed frequently during their lifetimes for any of the developing manifestations of this entity. Genetic counseling should be included in the management of all patients with Sipple syndrome. (<i>JAMA</i>235:1136-1137, 1976)
Incorrect Terminology
Journal: JAMA (1982)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Error in Title
Journal: JAMA Neurology (2022)

Marieke P. Hoevenaar-Blom, PhD; Edo Richard, MD; Eric P. Moll van Charante, MD; Lennard L. van Wanrooij, PhD; Wim B. Busschers, PhD; Jan W. van Dalen, PhD; Wim A. van Gool, MD
The Sulphonamides and Antibiotics in Man and Animals
Journal: JAMA (1953)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Error in Methods Section and Figure
Authors: Chunyuan Qiu, Vimal Desai, Anny Xiang
Journal: JAMA Pediatrics (2021)

Rebecca N. Dudovitz, MD, MS; Paul J. Chung, MD, MS; Sarah Reber, PhD; David Kennedy, PhD; Joan S. Tucker, PhD; Steve Shoptaw, PhD; Kulwant K. Dosanjh, MA; Mitchell D. Wong, MD, PhD
Pediatric Cardiology
Authors: Richard D. Rowe
Journal: JAMA (1973)

<i>Cardiovascular Clinics</i>is a specialty production under the overall medical editorship of Dr. Albert N. Brest. On the surface, each volume looks like the older established "clinics" of another publisher, yet it is issued irregularly. Because of this, even medical libraries seem to have difficulty classifying the series as individual monographs or as a journal. The minor irritation resulting from this spasmodic appearance is frequently well worth tolerating. This volume on pediatric cardiology is a good example. The issue is edited by Mary Allen Engle and dedicated to two of her heroes: Helen B. Taussig and the late Alfred E. Blalock. Dr. Engle has gathered contributions from members of her own center in New York and has called on a number of colleagues in other institutions to produce an impressive and authoritative collection of position papers on modern pediatric cardiology. Certain areas of development, particularly the normal morphology of the
Rare Distribution of Sclerotic Bony Lesions in Multiple Myeloma
Authors: Yuhua Wang, Ye Liu, Le Ma, Caixia An, Wanchun Zhang
Journal: Clinical Nuclear Medicine (2022)

A 66-year-old man was referred to our hospital due to a newly discovered left chest wall mass, which was diagnosed as plasmacytoma on biopsy. The patient underwent 18F-FDG PET/CT scanning before treatment. PET imaging revealed intense FDG signal in osseous lesions, and the CT showed most of the lesions were osteoblastic. The osseous lesions were predominantly localized to the humerus, femur, tibia, and phalanx of toe.
The Missouri controversy: is NMR ready for clinical use?
Authors: D. M. Fenichel
Journal: JAMA (1983)

Nuclear magnetic resonance (NMR) is about to leave the strictly experimental realm and—at least to a degree—enter the clinical world of two mediumsized hospitals in Central Missouri. The state's Health Facilities Review Committee (HFRC) has granted Columbia Regional Hospital and Boone Hospital Center, both in Columbia, each permission to purchase and operate an NMR scanner. Both hospitals have CT scanners which will be used, they say, as a complement to NMR. The decision has sparked controversy and potentially opened the floodgates for other hospitals seeking to offer the new technology. An important factor is that NMR still is considered an investigational device by the Food and Drug Administration. There are two types of NMR machines. One, employing a resistive magnet, is powered by a constant electrical current and is water cooled. It weighs about 2,700 kg (6,000 lb), now costs less than $1 million, and primarily is limited
DADP: Dynamic abnormality detection and progression for longitudinal knee magnetic resonance images from the Osteoarthritis Initiative
Authors: Chao Huang, Zhenlin Xu, Zhengyang Shen, Tianyou Luo, Tengfei Li, Daniel Nissman, Amanda Nelson, Yvonne Golightly, Marc Niethammer, Hongtu Zhu
Journal: Medical Image Analysis (2022)
The “All of Us” Research Program
Authors: Joshua C Denny, Joni L Rutter, David B Goldstein, Anthony Philippakis, Jordan W Smoller, Gwynne Jenkins, Eric Dishman
Journal: New England Journal of Medicine (2019)

Knowledge gained from observational cohort studies has dramatically advanced the prevention and treatment of diseases. Many of these cohorts, however, are small, lack diversity, or do not provide comprehensive phenotype data. The All of Us Research Program plans to enroll a diverse group of at least 1 million persons in the United States in order to accelerate biomedical research and improve health. The program aims to make the research results accessible to participants, and it is developing new approaches to generate, access, and make data broadly available to approved researchers. All of Us opened for enrollment in May 2018 and currently enrolls participants 18 years of age or older from a network of more than 340 recruitment sites. Elements of the program protocol include health questionnaires, electronic health records (EHRs), physical measurements, the use of digital health technology, and the collection and analysis of biospecimens. As of July 2019, more than 175,000 participants had contributed biospecimens. More than 80% of these participants are from groups that have been historically underrepresented in biomedical research. EHR data on more than 112,000 participants from 34 sites have been collected. The All of Us data repository should permit researchers to take into account individual differences in lifestyle, socioeconomic factors, environment, and biologic characteristics in order to advance precision diagnosis, prevention, and treatment.
PUBLIC HEALTH.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Normal Cerebral Angiogram
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Placental Mammals Acquired Functional Sequences in NRK for Regulating the CK2–PTEN–AKT Pathway and Placental Cell Proliferation
Authors: Beni Lestari, Satomi Naito, Akinori Endo, Hidenori Nishihara, Akira Kato, Erika Watanabe, Kimitoshi Denda, Masayuki Komada, Toshiaki Fukushima
Journal: Molecular Biology and Evolution (2022)

Abstract The molecular evolution processes underlying the acquisition of the placenta in eutherian ancestors are not fully understood. Mouse NCK-interacting kinase (NIK)-related kinase (NRK) is expressed highly in the placenta and plays a role in preventing placental hyperplasia. Here, we show the molecular evolution of NRK, which confers its function for inhibiting placental cell proliferation. Comparative genome analysis identified NRK orthologs across vertebrates, which share the kinase and citron homology (CNH) domains. Evolutionary analysis revealed that NRK underwent extensive amino acid substitutions in the ancestor of placental mammals and has been since conserved. Biochemical analysis of mouse NRK revealed that the CNH domain binds to phospholipids, and a region in NRK binds to and inhibits casein kinase-2 (CK2), which we named the CK2-inhibitory region (CIR). Cell culture experiments suggest the following: 1) Mouse NRK is localized at the plasma membrane via the CNH domain, where the CIR inhibits CK2. 2) This mitigates CK2-dependent phosphorylation and inhibition of PTEN and 3) leads to the inhibition of AKT signaling and cell proliferation. Nrk deficiency increased phosphorylation levels of PTEN and AKT in mouse placenta, supporting our hypothesis. Unlike mouse NRK, chicken NRK did not bind to phospholipids and CK2, decrease phosphorylation of AKT, or inhibit cell proliferation. Both the CNH domain and CIR have evolved under purifying selection in placental mammals. Taken together, our study suggests that placental mammals acquired the phospholipid-binding CNH domain and CIR in NRK for regulating the CK2–PTEN–AKT pathway and placental cell proliferation.
Marriages
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE JOURNAL SPECIAL TRAIN.
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Error in Title and Text
Authors: Delfina Janiri, Georgios Kotzalidis, Gabriele Sani
Journal: JAMA Psychiatry (2021)

Regarding the methodological concerns raised by Marx and colleagues on criterion A, all patients in the study sought and received treatment at the emergency department, where their clinical conditions were considered severe.Consistently, 81% of participants were hospitalized.Medical events and injuries related to COVID-19 were assessed during the interview according to the CAPS-5 2 and the Life Events Checklist for DSM-5 (LEC-5). 5 Patients were asked to describe their traumatic experience in their own words, then the interviewer asked for more details regarding the event.All participants with PTSD reported to have directly experienced life-threatening medical symptoms and/or personally witnessed the death of other patients at the emergency department or during hospitalization.We understand Marx and colleagues' surprise that in our study the only acute COVID-19 characteristic associated with PTSD diagnosis was delirium or agitation.This result may be explained in light of the fact that COVID-19 is a life-threating illness per se and was recently reported to be the leading cause of death in the US. 6 Accordingly, our data may be related to the unpredictable severity of the illness, which can quickly escalate to serious and possibly life-threatening.In the PTSD group, we found more persistent medical symptoms specifically related to COVID-19 (ie, fatigue, dyspnea, ageusia, and dysgeusia), compared with the non-PTSD group.These results seem to suggest that the characteristics of both the acute phase and postacute phase of COVID-19 might contribute to patients reexperiencing trauma associated with the illness.Regarding the severity of symptoms, the mean (SD) CAPS-5 score differed significantly for patients with PTSD (38.80 [10.32]) and those without PTSD (4.96 [5.11]) (P < .001).In patients reporting PTSD, mean symptom severity was within the moderate-severity range, which often requires therapeutic intervention.Nevertheless, the CAPS-5 total score in the PTSD group ranged from 14 to 57, covering a wide range of degrees of severity.Future studies could stratify patients according to PTSD symptom severity to better identify factors associated with PTSD, as well as protective measures, and to help design therapeutic and prevention strategies.